Docoh
Loading...

ZYNE Zynerba Pharmaceuticals

APP
Utility
Treatment of Fragile X Syndrome with Cannabidiol
30 Dec 21
The present technology relates to a method of treating one or more symptoms of Full Methylation (Fmet) Fragile X Syndrome in a subject that includes administering an effective amount of cannabidiol to the subject such that one or more symptoms of Fragile X Syndrome are treated.
James Griesser, Thomas W. Dobbins, Terri Sebree
Filed: 28 Jun 21
APP
Utility
Treatment of Fragile X Syndrome and Autism Spectrum Disorder with Cannabidiol
2 Dec 21
The present technology relates to a method of treating one or more behavioral symptoms of autism spectrum disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
Terri Sebree, Donna Gutterman, Carol O'Neill, Joseph Palumbo
Filed: 25 May 21
APP
Utility
Treatment of SYNGAP1 Encephalopathy
18 Mar 21
The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.
Terri Sebree, John Messenheimer, Donna Gutterman
Filed: 16 Sep 20
APP
Utility
Prodrugs of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same
18 Feb 21
Described herein are Δ9-THC prodrugs, methods of making Δ9-THC prodrugs, formulations comprising Δ9-THC prodrugs and methods of using Δ9-THC.
Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammell, Jeffrey Lynn Howard
Filed: 28 Aug 20
APP
Utility
Synthetic Transdermal Cannabidiol for the Treatment of Focal Epilepsy In Adults
4 Feb 21
The present technology relates to a method of reducing seizure frequency in a subject having epilepsy by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced.
Donna Gutterman, Terri Sebree, Ted Smith, John Messenheimer
Filed: 18 Aug 20
APP
Utility
Treatment of Fragile X Sydrome with Cannabidiol
18 Nov 20
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
Filed: 5 Aug 20
GRANT
Utility
Treatment of fragile x syndrome with cannabidiol
31 Aug 20
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
Filed: 6 Oct 19
APP
Utility
Prodrugs of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same
5 Aug 20
Described herein are Δ9-THC prodrugs, methods of making Δ9-THC prodrugs, formulations comprising Δ9-THC prodrugs and methods of using Δ9-THC.
Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammell, Jeffrey Lynn Howard
Filed: 2 Feb 20
APP
Utility
Treatment of Autism with Cannabidiol
8 Jul 20
The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
Filed: 7 Jan 20
APP
Utility
Treatment of 22Q11.2 Deletion Syndrome with Cannabidiol
17 Jun 20
The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q11.2 deletion syndrome are treated in the subject
Terri Sebree, Donna Gutterman
Filed: 11 Dec 19
APP
Utility
Methods of Treatment of Osteoarthritis with Transdermal Cannabidiol Gel
3 Jun 20
A pharmaceutical composition, and methods for using a pharmaceutical composition, for treating osteoarthritis in a subject in need thereof, the pharmaceutical composition including cannabidiol or a pharmaceutically acceptable salt thereof; and especially wherein administration of the cannabidiol is by a transdermal pharmaceutical gel composition.
Nancy Tich, John Messenheimer, Donna Gutterman, Daniel Clauw
Filed: 11 Feb 20
GRANT
Reissue
Use of cannabidiol prodrugs in pharmaceutical compositions
2 Mar 20
Described herein are cannabidiol prodrugs used in pharmaceutical compositions as well as microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal.
Audra Lynn Strinchcomb, Stan Lee Banks, Miroslaw Jerzy Golinski, Jeffrey Lynn Howard, Dana Carmel Hammel
Filed: 12 Dec 18
GRANT
Utility
Treatment of autism with cannabidiol
24 Feb 20
The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
Filed: 13 May 19
APP
Utility
Treatment of Fragile X Syndrome with Cannabidiol
29 Jan 20
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
Filed: 6 Oct 19
APP
Utility
Prodrugs of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same
22 Jan 20
Described herein are Δ9-THC prodrugs, methods of making Δ9-THC prodrugs, formulations comprising Δ9-THC prodrugs and methods of using Δ9-THC.
Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammell, Jeffrey Lynn Howard
Filed: 28 Jul 19
GRANT
Utility
Treatment of fragile X syndrome with cannabidiol
11 Nov 19
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
Filed: 15 Jan 19
  • 1
Patents are sorted by USPTO publication date, most recent first